4//SEC Filing
Fridriksdottir Hafrun 4
Accession 0001209191-21-032252
CIK 0000818686other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 7:45 AM ET
Size
10.0 KB
Accession
0001209191-21-032252
Insider Transaction Report
Form 4
Fridriksdottir Hafrun
Executive VP, Global R&D
Transactions
- Sale
Ordinary Shares
2021-05-11$10.22/sh−19,066$194,830→ 92,271.514 total - Exercise/Conversion
Ordinary Shares
2021-05-11+37,884→ 111,337.514 total - Exercise/Conversion
Restricted Share Units
2021-05-11−37,884→ 0 total→ Ordinary Shares (37,884 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.205 to $10.230, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001561458
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 7:45 AM ET
- Size
- 10.0 KB